Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
09 02 2021
09 02 2021
Historique:
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
17
2
2021
Statut:
ppublish
Résumé
Endurance exercise is effective in improving peak oxygen consumption (peak V̇o2) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak V̇o2 in patients with HFpEF. Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3 × 38 minutes/week), moderate continuous training (5 × 40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). Primary end point was change in peak V̇o2 after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. Among 180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). Among patients with HFpEF, there was no statistically significant difference in change in peak V̇o2 at 3 months between those assigned to high-intensity interval vs moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. ClinicalTrials.gov Identifier: NCT02078947.
Identifiants
pubmed: 33560320
pii: 2776199
doi: 10.1001/jama.2020.26812
pmc: PMC7873782
doi:
Banques de données
ClinicalTrials.gov
['NCT02078947']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
542-551Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
JAMA. 2016 Jan 5;315(1):36-46
pubmed: 26746456
Card Fail Rev. 2016 Nov;2(2):95-101
pubmed: 28785460
J Appl Physiol (1985). 2015 Sep 15;119(6):753-8
pubmed: 25190739
Heart Fail Rev. 2019 Jul;24(4):535-547
pubmed: 31032533
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Circ Heart Fail. 2010 Nov;3(6):659-67
pubmed: 20852060
Circulation. 2017 Feb 28;135(9):839-849
pubmed: 28082387
Eur J Prev Cardiol. 2020 Nov;27(16):1733-1743
pubmed: 31964186
Clin Trials. 2015 Aug;12(4):418-23
pubmed: 26033877
Med Sci Sports Exerc. 2012 May;44(5):776-85
pubmed: 22005747
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
ESC Heart Fail. 2018 Feb;5(1):53-62
pubmed: 29210202
JAMA. 2013 Feb 27;309(8):781-91
pubmed: 23443441
Eur Heart J. 2007 Oct;28(20):2539-50
pubmed: 17428822
Circ Heart Fail. 2015 Jan;8(1):209-20
pubmed: 25605639
Am Heart J. 2012 Dec;164(6):869-77
pubmed: 23194487
Circ Heart Fail. 2016 Jun;9(6):
pubmed: 27266854
Heart Fail Rev. 2018 Mar;23(2):147-156
pubmed: 29411216
Am J Cardiol. 2014 Feb 1;113(3):504-10
pubmed: 24342763
J Am Coll Cardiol. 2013 Aug 13;62(7):584-92
pubmed: 23665370
Int J Cardiol. 2018 Dec 15;273:147-154
pubmed: 30193792
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Eur J Heart Fail. 2019 Jan;21(1):125-127
pubmed: 30468294
J Am Coll Cardiol. 2011 Oct 18;58(17):1780-91
pubmed: 21996391
J Am Coll Cardiol. 2017 Mar 7;69(9):1129-1142
pubmed: 28254175
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):249-67
pubmed: 19440156
J Appl Physiol (1985). 1986 Jun;60(6):2020-7
pubmed: 3087938
JAMA. 2009 Apr 8;301(14):1439-50
pubmed: 19351941
Eur J Prev Cardiol. 2014 Nov;21(2 Suppl):18-25
pubmed: 25354950
J Am Coll Cardiol. 2012 Jul 10;60(2):120-8
pubmed: 22766338
Am Heart J. 2005 Oct;150(4):707-15
pubmed: 16209970
JAMA. 2002 Nov 6;288(17):2144-50
pubmed: 12413374
Eur J Heart Fail. 2015 Mar;17(3):263-72
pubmed: 25655080
Heart Lung. 2004 Jul-Aug;33(4):210-8
pubmed: 15252410
Heart Lung Circ. 2018 Jan;27(1):9-21
pubmed: 28870770
Circulation. 2016 Jun 14;133(24):e694-711
pubmed: 27143685